fda glp-1 compounding enforcement news october 2025 New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our March 31, 2025: Senator asks

Now, a new study provides the first randomized, placebo-controlled clinical evidence that semaglutide, a widely used GLP-1 drug, slows down the accumulation of biological aging markers in the DNA of adults with HIV

Je le commanderais nouveau 15 fvrier 2026 Je l'ai achet pour un membre de la famille avec un trouble neurologique et il n'a pas remarqu beaucoup d'amlioration pour sa condition, mais cela ne lui a pas non plus caus d'effets secondaires ou indsirables

Best fit Maximum weight-loss potential Outcome signal Up to 22.5% mean loss Evidence cue SURMOUNT evidence Decision rhythm Week 1 / Weeks 4-8 / Months 3-6 Best-fit signals Choose Compounded Tirzepatide when these match your goal Maximum weight-loss potential Decision timeline What to expect as you compare Compounded Tirzepatide Timelines vary by goal, dose, baseline health, and consistency

Semaglutide is dosed once weekly